Video investigation · Peptides

A Chiropractor With a Peptide Store Says Migraine Has a Cure. We Checked.

Two million Instagram followers, a reel called "Migraines have a solution," and a store selling injectable peptides labeled for research use only.

Published Runtime 20:3524 sources
The chiropractor with a peptide storeVideo coming soon to the Migraine Truth channel

Trevor Bachmeyer has two million Instagram followers, a bio that says Doctor twice, and a three minute reel called "Migraines have a solution." Comment the word GONE and a bot sends you the research playbook. 8,160 people did, on that reel alone.

We checked who he is, what the playbook leads to, and every claim in the reel against the research. His words, next to the papers, the FDA's own pages and the California Board of Chiropractic Examiners' records.

Never stop or change a medication because a video told you to, and never inject anything sold "for research use only." If your migraine treatment isn't working, that is a conversation with a neurologist or headache specialist, not a comment section.

What the video covers

  1. The doctor with two million followers
  2. Who is talking
  3. License revoked
  4. One million patients, the math
  5. How he sells it
  6. Elite Biogenix, his store
  7. What the FDA says about research use only
  8. The Black Card, $24,997
  9. The claims
  10. Cortical spreading depression and the pump
  11. Your doctor isn't telling you
  12. Mitochondria and magnesium, the part he gets right
  13. Opioids
  14. Triptans
  15. The types are ridiculous
  16. High estrogen
  17. 99 percent of neurologists
  18. The research, zero trials
  19. Safety
  20. Who is in the comments
  21. It isn't just migraine
  22. The shape of the pitch
  23. Before you inject anything

Sources

  1. California Board of Chiropractic Examiners, license DC 29377. Accusation AC 2016-1085 (2016), Stipulated Settlement (2017), revocation Jul 8, 2020.
  2. NPPES NPI Registry, NPI 1215169222, taxonomy Chiropractor.
  3. Texas Occupations Code, Sections 104.003 and 104.004.
  4. trevorbachmeyer.com and elitebiogenix.com (product pages, research stacks, dosage calculator, terms), captured Nov 6, 2026.
  5. Instagram @drtrevorbachmeyer reels and captions, and his Rumble channel, captured Nov 6, 2026.
  6. FDA. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (category 2 list), updated April 2026. Entries for BPC-157, KPV, MOTs-C, Thymosin Beta-4 Fragment (TB-500), Cathelicidin LL-37, GHK-Cu.
  7. FDA warning letters to online peptide sellers, Mar 31 and Aug 24, 2026.
  8. FDA Pharmacy Compounding Advisory Committee, Jul 23-24, 2026.
  9. CBS News, Jul 30, 2026. Judge sentences peptide vendor (Paradigm Peptides) to nearly 6 years in prison.
  10. Charles AC, Baca SM. Cortical spreading depression and migraine. Nat Rev Neurol. 2013;9:637-44.
  11. De Fusco M, et al. Haploinsufficiency of ATP1A2 encoding the Na+/K+ pump alpha2 subunit associated with familial hemiplegic migraine type 2. Nat Genet. 2003;33:192-6.
  12. Holland S, et al. Evidence-based guideline update. NSAIDs and other complementary treatments for episodic migraine prevention in adults. Neurology. 2012;78:1346-53.
  13. Loder E, et al. Choosing wisely in headache medicine. The American Headache Society's list of five things physicians and patients should question. Headache. 2013;53:1651-9.
  14. Diener HC, et al. Pathophysiology, prevention, and treatment of medication overuse headache. Lancet Neurol. 2019;18:891-902.
  15. Curto M, et al. Profiling lasmiditan as a treatment option for migraine. Expert Opin Pharmacother. 2020;21:147-53.
  16. Shapiro RE, et al. Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors. J Headache Pain. 2019;20:90.
  17. Petersen CL, et al. Risk of stroke and myocardial infarction among initiators of triptans. JAMA Neurol. 2024;81:248-54.
  18. Roberto G, et al. Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine. Cephalalgia. 2015;35:118-31.
  19. MacGregor EA, et al. Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen. Neurology. 2006;67:2154-8.
  20. Shan Z, et al. SS-31 alleviated nociceptive responses and restored mitochondrial function in a headache mouse model. J Headache Pain. 2023;24:65.
  21. PubMed searches, Nov 6, 2026. (BPC-157) AND (Clinical Trial[pt] OR Randomized Controlled Trial[pt]) returned 0 results. (BPC-157 OR KPV OR MOTS-c OR SS-31 OR GHK-Cu OR LL-37 OR TB-500 OR semax) AND migraine[tiab] returned 1 result.
  22. Ashraf AR, et al. Multifactor quality and safety analysis of semaglutide products sold by online sellers without a prescription. J Med Internet Res. 2024;26:e65440.
  23. Breindahl T, et al. Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet. Drug Test Anal. 2015;7:164-72.
  24. Hailu KT, et al. Unregulated peptide use in the age of biohacking. Cureus. 2026;18:e110657.
Not medical advice. This is an educational review of public claims and published research. It isn't a diagnosis or a treatment plan. Never stop or change a medication because of something you read or watched online, including here. Talk with your doctor, neurologist or headache specialist about your own care. Spot an error? See how to request a correction.

More investigations

See all
ChiropracticVideo · 24:16
Brandon Brown

TikTok's Migraine Doc

We checked

A Texas chiropractor with 621K TikTok followers says most migraine comes from one small bone in your neck, and that his test can find it.
Lab testsVideo · 10:36
Kelli Yates, RDN

The Migraine Dietitian

We checked

A lot of what she says is right. She also sells migraine patients a $577 stool test, a $550 urine hormone panel and a food test with zero published studies.
Coaching programsVideo · 17:08
Kevin Wissman

The program that works every time

We checked

"Works every time" is how he describes his migraine coaching program. We watched the whole 52-minute sales video and checked every claim.